Contribution of the opioid system to alcohol aversion and alcohol drinking behavior

J. C. Froehlich, N. E. Badia-Elder, R. W. Zink, D. E. McCullough, Philip S Portoghese

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

The effect of blocking delta opioid receptors on alcohol aversion was examined in female alcohol-preferring (P) rats using a conditioned taste aversion (CTA) paradigm. In experiment 1, alcohol naive P rats were given i.p injections of 0.5, 1.0 or 1.5 g alcohol/kg BW or saline, paired with consumption of a banana-flavored solution during 5 conditioning trials. Alcohol in a dose of 0.5 g/kg was not aversive while the two higher doses (1.0 and 1.5 g/kg) were both aversive in the CTA paradigm. In experiment 2, the effect of the selective delta opioid receptor antagonist, naltrindole (NTI), on alcohol aversion was examined. Rats were pretreated with NTI in doses of 2.5, 5.0, 10.0 or 20.0 mg/kg before conditioning using the nonaversive dose of alcohol from Experiment 1. As in experiment 1, the 0.5 g/kg dose of alcohol did not produce a CTA. Administration of NTI alone in doses of 2.5, 5.0 or 10.0 mg/kg did not produce a CTA. However, when the nonaversive dose of alcohol (0.5 g/kg) was combined with NTI in a dose of either 5.0 or 10.0 mg/kg, an aversion to alcohol was seen. The highest dose of NTI (20 mg/kg) produced a CTA when given either alone and in combination with alcohol. The results indicate that blocking the action of opioid peptides at the delta opioid receptor can make a nonaversive dose of alcohol aversive which suggests that opioid peptides, acting via the delta opioid receptor, play an important role in regulating alcohol aversion.

Original languageEnglish (US)
Pages (from-to)284-292
Number of pages9
JournalJournal of Pharmacology and Experimental Therapeutics
Volume287
Issue number1
StatePublished - Dec 1 1998

Fingerprint

Drinking Behavior
Alcohol Drinking
naltrindole
Opioid Analgesics
Alcohols
delta Opioid Receptor
Opioid Peptides
Musa
Narcotic Antagonists

Cite this

Contribution of the opioid system to alcohol aversion and alcohol drinking behavior. / Froehlich, J. C.; Badia-Elder, N. E.; Zink, R. W.; McCullough, D. E.; Portoghese, Philip S.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 287, No. 1, 01.12.1998, p. 284-292.

Research output: Contribution to journalArticle

Froehlich, J. C. ; Badia-Elder, N. E. ; Zink, R. W. ; McCullough, D. E. ; Portoghese, Philip S. / Contribution of the opioid system to alcohol aversion and alcohol drinking behavior. In: Journal of Pharmacology and Experimental Therapeutics. 1998 ; Vol. 287, No. 1. pp. 284-292.
@article{8d1d4f6093a74ecaaf11257109a50bb4,
title = "Contribution of the opioid system to alcohol aversion and alcohol drinking behavior",
abstract = "The effect of blocking delta opioid receptors on alcohol aversion was examined in female alcohol-preferring (P) rats using a conditioned taste aversion (CTA) paradigm. In experiment 1, alcohol naive P rats were given i.p injections of 0.5, 1.0 or 1.5 g alcohol/kg BW or saline, paired with consumption of a banana-flavored solution during 5 conditioning trials. Alcohol in a dose of 0.5 g/kg was not aversive while the two higher doses (1.0 and 1.5 g/kg) were both aversive in the CTA paradigm. In experiment 2, the effect of the selective delta opioid receptor antagonist, naltrindole (NTI), on alcohol aversion was examined. Rats were pretreated with NTI in doses of 2.5, 5.0, 10.0 or 20.0 mg/kg before conditioning using the nonaversive dose of alcohol from Experiment 1. As in experiment 1, the 0.5 g/kg dose of alcohol did not produce a CTA. Administration of NTI alone in doses of 2.5, 5.0 or 10.0 mg/kg did not produce a CTA. However, when the nonaversive dose of alcohol (0.5 g/kg) was combined with NTI in a dose of either 5.0 or 10.0 mg/kg, an aversion to alcohol was seen. The highest dose of NTI (20 mg/kg) produced a CTA when given either alone and in combination with alcohol. The results indicate that blocking the action of opioid peptides at the delta opioid receptor can make a nonaversive dose of alcohol aversive which suggests that opioid peptides, acting via the delta opioid receptor, play an important role in regulating alcohol aversion.",
author = "Froehlich, {J. C.} and Badia-Elder, {N. E.} and Zink, {R. W.} and McCullough, {D. E.} and Portoghese, {Philip S}",
year = "1998",
month = "12",
day = "1",
language = "English (US)",
volume = "287",
pages = "284--292",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "1",

}

TY - JOUR

T1 - Contribution of the opioid system to alcohol aversion and alcohol drinking behavior

AU - Froehlich, J. C.

AU - Badia-Elder, N. E.

AU - Zink, R. W.

AU - McCullough, D. E.

AU - Portoghese, Philip S

PY - 1998/12/1

Y1 - 1998/12/1

N2 - The effect of blocking delta opioid receptors on alcohol aversion was examined in female alcohol-preferring (P) rats using a conditioned taste aversion (CTA) paradigm. In experiment 1, alcohol naive P rats were given i.p injections of 0.5, 1.0 or 1.5 g alcohol/kg BW or saline, paired with consumption of a banana-flavored solution during 5 conditioning trials. Alcohol in a dose of 0.5 g/kg was not aversive while the two higher doses (1.0 and 1.5 g/kg) were both aversive in the CTA paradigm. In experiment 2, the effect of the selective delta opioid receptor antagonist, naltrindole (NTI), on alcohol aversion was examined. Rats were pretreated with NTI in doses of 2.5, 5.0, 10.0 or 20.0 mg/kg before conditioning using the nonaversive dose of alcohol from Experiment 1. As in experiment 1, the 0.5 g/kg dose of alcohol did not produce a CTA. Administration of NTI alone in doses of 2.5, 5.0 or 10.0 mg/kg did not produce a CTA. However, when the nonaversive dose of alcohol (0.5 g/kg) was combined with NTI in a dose of either 5.0 or 10.0 mg/kg, an aversion to alcohol was seen. The highest dose of NTI (20 mg/kg) produced a CTA when given either alone and in combination with alcohol. The results indicate that blocking the action of opioid peptides at the delta opioid receptor can make a nonaversive dose of alcohol aversive which suggests that opioid peptides, acting via the delta opioid receptor, play an important role in regulating alcohol aversion.

AB - The effect of blocking delta opioid receptors on alcohol aversion was examined in female alcohol-preferring (P) rats using a conditioned taste aversion (CTA) paradigm. In experiment 1, alcohol naive P rats were given i.p injections of 0.5, 1.0 or 1.5 g alcohol/kg BW or saline, paired with consumption of a banana-flavored solution during 5 conditioning trials. Alcohol in a dose of 0.5 g/kg was not aversive while the two higher doses (1.0 and 1.5 g/kg) were both aversive in the CTA paradigm. In experiment 2, the effect of the selective delta opioid receptor antagonist, naltrindole (NTI), on alcohol aversion was examined. Rats were pretreated with NTI in doses of 2.5, 5.0, 10.0 or 20.0 mg/kg before conditioning using the nonaversive dose of alcohol from Experiment 1. As in experiment 1, the 0.5 g/kg dose of alcohol did not produce a CTA. Administration of NTI alone in doses of 2.5, 5.0 or 10.0 mg/kg did not produce a CTA. However, when the nonaversive dose of alcohol (0.5 g/kg) was combined with NTI in a dose of either 5.0 or 10.0 mg/kg, an aversion to alcohol was seen. The highest dose of NTI (20 mg/kg) produced a CTA when given either alone and in combination with alcohol. The results indicate that blocking the action of opioid peptides at the delta opioid receptor can make a nonaversive dose of alcohol aversive which suggests that opioid peptides, acting via the delta opioid receptor, play an important role in regulating alcohol aversion.

UR - http://www.scopus.com/inward/record.url?scp=0032454064&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032454064&partnerID=8YFLogxK

M3 - Article

VL - 287

SP - 284

EP - 292

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 1

ER -